- Home
- SLXN vs CNFR Comparison
SLXN vs CNFR Comparison
Compare SLXN & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- CNFR
- Stock Information
- Founded
- SLXN 2008
- CNFR 2009
- Country
- SLXN Israel
- CNFR United States
- Employees
- SLXN N/A
- CNFR N/A
- Industry
- SLXN
- CNFR Property-Casualty Insurers
- Sector
- SLXN
- CNFR Finance
- Exchange
- SLXN NYSE
- CNFR Nasdaq
- Market Cap
- SLXN 6.9M
- CNFR 7.9M
- IPO Year
- SLXN N/A
- CNFR 2015
- Fundamental
- Price
- SLXN $0.95
- CNFR $0.76
- Analyst Decision
- SLXN Strong Buy
- CNFR
- Analyst Count
- SLXN 1
- CNFR 0
- Target Price
- SLXN $5.00
- CNFR N/A
- AVG Volume (30 Days)
- SLXN 1.2M
- CNFR 11.0K
- Earning Date
- SLXN 05-13-2025
- CNFR 05-14-2025
- Dividend Yield
- SLXN N/A
- CNFR N/A
- EPS Growth
- SLXN N/A
- CNFR N/A
- EPS
- SLXN N/A
- CNFR 1.96
- Revenue
- SLXN N/A
- CNFR $64,021,000.00
- Revenue This Year
- SLXN N/A
- CNFR $25.91
- Revenue Next Year
- SLXN N/A
- CNFR N/A
- P/E Ratio
- SLXN N/A
- CNFR $0.39
- Revenue Growth
- SLXN N/A
- CNFR N/A
- 52 Week Low
- SLXN $0.58
- CNFR $0.42
- 52 Week High
- SLXN $41.85
- CNFR $1.91
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- CNFR 47.88
- Support Level
- SLXN N/A
- CNFR $0.75
- Resistance Level
- SLXN N/A
- CNFR $0.85
- Average True Range (ATR)
- SLXN 0.00
- CNFR 0.03
- MACD
- SLXN 0.00
- CNFR -0.01
- Stochastic Oscillator
- SLXN 0.00
- CNFR 18.85
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.